滚动资讯
FierceBiotechAstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trialFierceBiotechRising costs push GE HealthCare to cut outlook as it restructures units and leadershipFierceBiotechTeva inks $700M Emalex buyout to bag near-approval Tourette drugFierceBiotechAstraZeneca restarts £300M investment in UK, but Merck not budgingCellSpatial organization and detection of social odors in mouse primary olfactory systemCellUnbiased niche labeling maps immune-excluded niche in bone metastasisCellA spatial code governs olfactory receptor choice and aligns sensory maps in the nose and brainCellErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imagingCellSensing endoplasmic reticulum redox state by ethylene receptorsBioPharma DiveChiesi to buy KalVista in $1.9B deal for rare disease drugEndpoints NewsBristol Myers reaches a crossroads as a make-or-break year takes shapeEndpoints NewsPfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
FierceBiotech 2026年4月29日

AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial

AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial

原文
暂时没有全文，请查看原始来源。